-
EXCLUSIVE: Psychedelics Pioneer J.R. Rahn Unpacks Decision To Leave MindMed As CEO
Thursday, June 10, 2021 - 10:37am | 784Mind Medicine (MindMed) Inc (NASDAQ: MNMD) (NEO: MMED), a biotech company focused on the field of psychedelics, formally announced this week that J.R. Rahn, the company’s co-founder and CEO, would step down. Benzinga spoke with Rahn on what the transition means for MindMed, the industry ...
-
Fintech Focus For May 3, 2021
Sunday, May 2, 2021 - 7:25pm | 1759Quote To Start The Day: “In three words I can sum up everything I've learned about life: it goes on.” Source: Robert Frost One Big Thing In Fintech: Robinhood, the free-trading app that helped drive a surge in retail investing during the pandemic, has switched to using JPMorgan...
-
Fintech Focus Roundup For May 2, 2021
Sunday, May 2, 2021 - 8:17am | 975Apex Fintech Solutions Announces Blow-Out Earnings Ahead Of NYSE Listing What Happened: Blank-check company Northern Star Investment Corporation II announced that Apex Fintech Solutions LLC, a business-to-business platform that powers innovation in fintech, investing and wealth management,...
-
Exclusive: MindMed's Nasdaq Listing Enables Institutions Diversified Access To A New Age Of Medicine
Friday, April 30, 2021 - 9:05am | 1137Mind Medicine (MindMed) Inc (NASDAQ: MNMD) (NEO: MMED), a leading medicine biotech company in psychedelics, this week began trading on the Nasdaq exchange. In light of the momentous occasion, Benzinga spoke with MindMed co-founder and CEO J.R. Rahn, as well as board member Kevin O’Leary...
-
Psyched: MindMed, Atai Head For Nasdaq, Psychedelics Search Platforms Grow, Champignon Brands Resumes Trading
Monday, April 26, 2021 - 7:58am | 940Two of the most highly funded companies in the psychedelics space announced plans last week to list on the Nasdaq exchange. Months after submitting an application to uplist its shares from Toronto’s NEO exchange, MindMed (OTCQB: MMEDF) confirmed it will commence trading on the Nasdaq Capital...
-
Psyched: MindMed's 2020 Financials, Psychedelics ETF Rebalancing, Country's First Psychedelics Masters Degree
Tuesday, April 6, 2021 - 11:39am | 1305MindMed Posts 2020 Financials, New MDMA Dosing Study and 18-MC Patent Application MindMed (OTCQB:MMEDF) released its full-year 2020 financial results. The company posted a net and comprehensive loss of $35.1 million for the year ended Dec. 31, 2020. Its total assets at the end of the...
-
Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week
Tuesday, April 6, 2021 - 9:22am | 1992Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap. In This Week’s Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelics Industry News Stories for the Week of March 29th – April 4th, 2021. Without further ado...
-
MindMed Reveals Results Of A Study On Personalized MDMA Dosing
Monday, April 5, 2021 - 1:17pm | 448Psychedelic medicine biotech company MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ) reported Monday the results of a study on MDMA dosing optimization utilizing personalized medicine. The study was conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland. The company said it...
-
Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week
Monday, March 29, 2021 - 12:46pm | 2127Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap. In This Week’s Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelics Industry News Stories for the Week of March 22nd – 28th, 2021. Without further ado,...
-
Psyched: The Patents Dilemma, Compass 2020 Earnings, New Psilocybin Bill In NY
Monday, March 15, 2021 - 12:40pm | 1591These days, the psychedelics finds itself in the midst of a public debate around the moral implications of patents and intellectual property for certain medicines and treatments. The conversation began last month when Compass Pathways (NASDAQ: CMPS) introduced a series of patent...
-
Fintech Focus Roundup For February 20, 2020
Saturday, February 20, 2021 - 8:21am | 1565Fintech Spotlight: How Morpher Lets You Buy Apple, On A Weekend, With As Little As $1 When typically discussed, blockchain lacks a utility component. That’s what Morpher CEO Martin Fröhler is looking to change. Fröhler is a mathematician, with a background in quantitative finance,...
-
Cannabis Movers & Shakers: TILT, MindMed, EnWave, Zelira
Friday, February 19, 2021 - 10:21am | 747TILT Hires Two Compliance Experts TILT Holdings Inc. (CSE: TILT) (OTCQX: TLLTF) strengthened its leadership team by welcoming Nicole Moyers as vice president of compliance and Patrick Beyea as director of compliance. Moyers has extensive experience in government affairs, public service...
-
MindMed To Buy AI Medicine Company HealthMode For CA$42M
Thursday, February 18, 2021 - 1:39pm | 487MindMed (NEO: MMED) (OTCQB: MMEDF) agreed to buy HealthMode, an artificial intelligence medicine company, in a CA$41.56 million (US$32.5 million) stock and cash deal. The psychedelic biotech company confirmed Thursday it will acquire a digital medicine and therapeutics startup that relies...
-
Psyched: MindMed Enters Psychedelics 2.0, Mind Cure Raises $18M, Mydecine Raises $13M
Wednesday, February 17, 2021 - 12:44pm | 829Mind Cure Closes $18M Raise Mind Cure Health Inc. (CSE:MCUR) recently announced the closing of a CA$23 Million ($18.1 million) offering. The company issued approximately 38 million units, consisting of one share and one half of a share purchase warrant, at CA$0.60 per unit. The proceeds...
-
The Horizons Psychedelic Stock Index ETF, As Told By Its Fund Manager
Thursday, February 11, 2021 - 11:33am | 1149On January 27, the Horizons Psychedelic Stock Index ETF (NEO:PSYK) became the first exchange traded fund to focus solely on the psychedelics industry. Horizons ETFs CEO Steve Hawkins sat down with Benzinga to discuss the listing, which brought in approximately CA$25 million ($19.4 million) in...